Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment-Reference-Cited by-同舟云学术

Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment

Published:2018-08-22 Issue:11 Volume:25 Page:1331-1340
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Agarwal K.¹^ORCID,Ahn S. H.²,Elkhashab M.³,Lau A. H.⁴,Gaggar A.⁴,Bulusu A.⁴,Tian X.⁴,Cathcart A. L.⁴,Woo J.⁴,Subramanian G. M.⁴,Andreone P.⁵^ORCID,Kim H. J.⁶,Chuang W. L.⁷,Nguyen M. H.⁸^ORCID

Affiliation:

1. Institute of Liver Studies; Kings College Hospital; London UK

2. Brain Korea 21 Project of Medical Science; Yonsei University College of Medicine; Seoul Korea

3. Toronto Liver Centre; Toronto ON Canada

4. Gilead Sciences, Inc.; Foster City CA USA

5. Center for the Study and Research on Hepatitis; Department of Medical and Surgical Sciences; University of Bologna; Bologna Italy

6. Chung-Ang University Hospital; Seoul South Korea

7. Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Taiwan

8. Stanford University Medical Center; Palo Alto CA USA

Funder

Gilead Sciences

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12942/fullpdf

Reference27 articles.

1. Organization WH Hepatitis B Fact Sheet http://www.who.int/mediacentre/factsheets/fs204/en/

2. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors;Fattovich;J Hepatol,2008

3. Hepatitis B virus infection-natural history and clinical consequences;Ganem;N Engl J Med,2004

4. Chronic hepatitis B virus infection;McMahon;Med Clin North Am,2014

5. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013;Mortality GBD, Causes of Death C;Lancet,2015

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod;Clinical and Translational Science;2024-08

2. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer;International Immunopharmacology;2024-08

3. HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study;Antibody Therapeutics;2024-07

4. Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation;The American Journal of Human Genetics;2024-06

5. TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism;Gut;2024-05-02